Critical appraisal of CRP measurement for the prediction of coronary heart disease events:new data and systematic review of 31 prospective cohorts by Shah, Tina et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Critical appraisal of CRP measurement for the prediction of
coronary heart disease events
Citation for published version:
Shah, T, Casas, JP, Cooper, JA, Tzoulaki, I, Sofat, R, McCormack, V, Smeeth, L, Deanfield, JE, Lowe, GD,
Rumley, A, Fowkes, FGR, Humphries, SE & Hingorani, AD 2009, 'Critical appraisal of CRP measurement
for the prediction of coronary heart disease events: new data and systematic review of 31 prospective
cohorts' International Journal of Epidemiology, vol 38, no. 1, pp. 217-31. DOI: 10.1093/ije/dyn217
Digital Object Identifier (DOI):
10.1093/ije/dyn217
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
International Journal of Epidemiology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
CARDIOVASCULAR DISEASE
Critical appraisal of CRP measurement for the
prediction of coronary heart disease events:
new data and systematic review of
31 prospective cohorts
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Accepted 3 September 2008
Background Non-uniform reporting of relevant relationships and metrics
hampers critical appraisal of the clinical utility of C-reactive protein
(CRP) measurement for prediction of later coronary events.
Methods We evaluated the predictive performance of CRP in the Northwick
Park Heart Study (NPHS-II) and the Edinburgh Artery Study (EAS)
comparing discrimination by area under the ROC curve (AUC),
calibration and reclassification. We set the findings in the context
of a systematic review of published studies comparing different
available and imputed measures of prediction. Risk estimates per-
quantile of CRP were pooled using a random effects model to infer
the shape of the CRP-coronary event relationship.
Results NPHS-II and EAS (3441 individuals, 309 coronary events): CRP alone
provided modest discrimination for coronary heart disease (AUC 0.61
and 0.62 in NPHS-II and EAS, respectively) and only modest
improvement in the discrimination of a Framingham-based risk
score (FRS) (increment in AUC 0.04 and –0.01, respectively). Risk
models based on FRS alone and FRSþCRP were both well calibrated
and the net reclassification improvement (NRI) was 8.5% in NPHS-II
and 8.8% in EAS with four risk categories, falling to 4.9% and 3.0% for
10-year coronary disease risk threshold of 15%. Systematic review (31
prospective studies 84 063 individuals, 11 252 coronary events):
pooled inferred values for the AUC for CRP alone were 0.59 (0.57,
0.61), 0.59 (0.57, 0.61) and 0.57 (0.54, 0.61) for studies of <5, 5–10
and410 years follow up, respectively. Evidence from 13 studies (7201
cases) indicated that CRP did not consistently improve performance
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of the Framingham risk score when assessed by discrimination, with
AUC increments in the range 0–0.15. Evidence from six studies (2430
cases) showed that CRP provided statistically significant but quanti-
tatively small improvement in calibration of models based on estab-
lished risk factors in some but not all studies. The wide overlap of CRP
values among people who later suffered events and those who did not
appeared to be explained by the consistently log-normal distribution
of CRP and a graded continuous increment in coronary risk across the
whole range of values without a threshold, such that a large
proportion of events occurred among the many individuals with
near average levels of CRP.
Conclusions CRP does not perform better than the Framingham risk equation
for discrimination. The improvement in risk stratification or
reclassification from addition of CRP to models based on
established risk factors is small and inconsistent. Guidance on the
clinical use of CRP measurement in the prediction of coronary
events may require updating in light of this large comparative
analysis.
Keywords C-reactive protein, prediction, coronary heart disease, primary
prevention, risk stratification
Introduction
Primary prevention of cardiovascular events currently
involves targeting interventions to those at high
absolute risk, identified using risk-prediction instru-
ments such as the Framingham equation, that
integrate information on established risk factors.1
However, a large proportion of events occur among
individuals with near average levels of continuous risk
factors,2 or at intermediate Framingham risk. With
emerging evidence on the role of inflammation in
atherosclerosis, there is interest in the potential pre-
dictive utility of C-reactive protein (CRP), a sensitive
circulating biomarker of inflammation.3 Nearly, 40
reports from prospective studies and three meta-
analyses4–6 indicate a highly consistent, moderate
association of CRP with later coronary heart disease
(CHD) events among clinically healthy subjects. In
2004, consensus statements from population, labora-
tory science and clinical practice expert committees
convened by the American Heart Association/Centres
for Disease Control (AHA/CDC) indicated that ‘CRP
may be used at the discretion of the physician as part
of a global coronary risk assessment in adults without
known cardiovascular disease’, and that a CRP value
above a cut-point of 3 mg/l was indicative of subjects
at high risk.7–10 However, all committees highlighted
gaps in the available data and made recommenda-
tions for additional research. Although several CRP
tests have received FDA approval, recent publications
have highlighted ongoing debate on the real utility
of CRP measurement in comparison with or as a
supplement to conventional risk assessment of
CHD,11–15 leaving clinicians, policymakers and
patients uncertain as to the value of this test.
Reporting of measures of predictive performance in
the many prospective studies of CRP has been
inconsistent. Although measures of the strength of
the association, e.g. using hazard or odds ratios, have
achieved greater prominence (and are important in
aetiological analysis), these measures provide limited
information on predictive utility.16,17 To complicate
matters, there is debate on the most appropriate
metric for the evaluation of a new marker.
Established measures include discrimination [the
ability of a marker to distinguish individuals who
will develop an event, assessed by sensitivity and
specificity and the area under the ROC curve (AUC)],
and calibration (use of a risk model to order or
stratify risk, whose accuracy is assessed by tests that
evaluate model fit). More recently, concerns that
neither of these approaches provides a fair evaluation
of a new marker has motivated interest in the
development of new measures of predictive utility.18
A method proposed recently involves quantifying the
extent to which a new marker shifts individuals
between categories of CHD risk initially determined
using established risk models (reclassification).19
A 2006 NHLBI workshop on CRP included the
following recommendations: (i) ‘analyses of individual
and pooled data from existing and new epidemiologic
studies (or ancillary studies) to examine whether CRP
measurement improves CVD risk prediction beyond
traditional risk factors and can help target who should
be treated’; (ii) research to assess ‘whether replacing a
traditional risk factor(s) with CRP (or other newly
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discovered risk predictors) could improve CVD risk
prediction’; and (iii) research on ‘the shape of the dose-
response curve’ (http://www.nhlbi.nih.gov/meetings/
workshops/crp/report.htm). We therefore assessed the
performance of CRP as a risk marker in the Northwick
Park Heart Study II (NPHS-II) and replicated the
findings in the Edinburgh Artery Study (EAS), two
population-based prospective studies. For these ana-
lyses we tested discrimination, calibration and reclassi-
fication to assess consistency between methods. Next,
we conducted a systematic review of prior prospective
studies that had examined the association of CRP and
CHD to assess consistency between studies. This review
differs importantly from prior overviews in this area in
that our focus was on the evaluation of the predictive
performance of CRP, rather than simply its association,
and involved inferring measures relevant to prediction
where these were unreported. Finally, we examined the
population distribution of CRP in all the studies, and
the shape of the relationship with CHD events, to better
understand the factors that could constrain perfor-
mance of this marker.
Methods
Northwick Park Heart Study II
NPHS-II is a prospective study of 3012 healthy
middle-aged men of European descent (age at
recruitment 50–64 years), with enrolment commenc-
ing in 1989.20 Nine general practices participated in
the study. The study was approved by the local
institutional review committee and all subjects pro-
vided written informed consent. Further details are
provided in the Supplementary Data.22–24
Edinburgh Artery Study
The EAS is a prospective study of 1592 European
descent individuals (809 men and 783 women) aged
55–74 years enroled in 1988. Individuals were selected
at random from 11 general practices serving a range
of socio-economic and geographical areas throughout
the city of Edinburgh, Scotland. Details of the study
recruitment and examination process have been
described elsewhere.21 Further details are provided
in the Supplementary Data.25
Statistical analyses in NPHS-II and EAS
Association
Log-transformations were conducted for non-
normally distributed data and for these variables
means are geometric and standard deviations approx-
imate. The association of CRP and risk of CHD events
is reported as a hazard ratio with 95% CI obtained
from a Cox proportional hazards model. Age-adjusted
incidence rates (cases/1000 person years) and
the absolute number of events are reported by tertile
of CRP and in categories defined by CRP cut-
points <1, 1–3 and 43 mg/l. Means and standard
deviations (SD) of log-transformed CRP in those who
suffered CHD events and those who remained event-
free were used to construct normal curves to
determine the overlap between the distributions in
the two groups.
Model discrimination
The performance of CRP for discrimination was
assessed by means of the disease detection rate (DR)
or sensitivity, i.e. the proportion of those who devel-
oped events who tested positive using CRP cut-points
corresponding to pre-set false-positive rates of 5%
(DR5) or 10% (DR10). In addition, we calculated the
positive predictive value of a CRP cut-point of 3 mg/l i.e.
the proportion of people with a CRP value43 mg/l who
suffered an event. The incremental effect on discrimi-
nation of adding CRP to the Framingham risk score
was summarized by means of the AUC and Harrell’s
C-statistic. The Harrell’s C-statistic from a Cox model is
conceptually analogous to the AUC estimated from
logistic models which allows for right-censored data
and variable time to follow up.16,26–28
Model calibration
The performance of risk estimates generated from Cox
models using Framingham variables alone,29 or with
the addition of CRP, was evaluated by ranking
participants according to one-fifths of predicted risk,
and comparing within each category, the predicted
and observed 10-year risks of CHD in NPHS-II and
17-year risks of CHD in EAS. The Akaike’s informa-
tion criterion (AIC) and Bayes information criterion
(BIC) were used to assess global fit using
Framingham variables alone or with CRP. The
Hosmer–Lemeshow chi-square statistic30 was used to
assess model fit. Small chi-square values indicate a
good calibration while values exceeding 20 (P< 0.01)
indicate significant lack of calibration.
Reclassification of CHD risk
The extent to which CRP reassigned individuals to
risk categories that better reflected their final outcome
was assessed using the NRI measure.19 For indivi-
duals who develop an event, risk classification is
considered improved if the individual moves to a
higher risk category with the addition of a marker,
and worsened if the individual moves to a lower one.
For individuals who remain healthy the converse
is true. For people who develop events, the difference
in the proportion of individuals moving up and the
proportion moving down a category is calculated. For
people remaining healthy, the proportion of indivi-
duals moving down minus the proportion moving up
a category is calculated. The NRI is obtained as the
sum of these two values. First, individuals were as-
signed to one of the following 10-year CHD risk
categories based on a model using established risk
factors: 0% to <5%, 5% to <10%, 10% to <15% and
515%, similar to previous reports.31 Next, the NRI
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was calculated following the addition of CRP to the
risk model. In a separate analysis, individuals were
assigned to one of two risk categories based on a
10-year CHD risk of 0% to <15% or 515%. This
allowed us to assess the potential effect of reclassi-
fication on the clinical decision to prescribe choles-
terol lowering therapy for primary prevention based
on thresholds for intervention advocated by UK
guidelines (e.g. NICE guidelines on primary preven-
tion with statins, http://www.nice.org.uk/guidance/).
In addition, to facilitate comparison with two prior
reports, reclassification tables were drawn to allow
comparison of the observed (actual) risk in each
category of predicted risk comparing models that
differed only in their inclusion or omission of CRP.
Systematic review
Search strategy and data extraction
Two electronic databases (Medline and EMBASE) were
searched up to and including August 2007 for all
prospective studies (including cohort, nested case–
control or case–cohort studies) of initially healthy
subjects evaluating the association between CRP
concentration and coronary events with no threshold
sample size. For the search, the MeSH terms,
‘C-reactive protein’ and ‘CRP’ in combination with
‘coronary’, ‘coronary heart disease’, ‘CHD’ and ‘CVD’
were used and the search was limited by the terms
‘human’ and ‘English Language’. Studies in which
total mortality was the only outcome reported
were excluded. See Supplementary Data and
Supplementary Figure 1 for further details.
Analysis
Measures relevant to the performance of a screening
test tended not to be reported in many of the
previously reported studies and we estimated some
of them as follows. We first extracted values of the
geometric mean CRP (and approximate SD) sepa-
rately for incident cases and those remaining free of
events (controls). Where the median was reported,
this was used as an estimate of the geometric mean
and approximate SD was calculated from the inter-
quartile range, assuming a log-normal distribution.
Where no measure of dispersion was reported,
an estimated SD based on pooled values from studies
that provided this measure was applied. These data
were then used to construct the log-normal distribu-
tions of CRP from each study for the cases and
controls separately, which permitted estimation of
study specific values for the DR (sensitivity) for a 5%
or 10% false-positive rate (DR5 and DR10), as
well as the AUC for CRP using methods reported
previously.17,27 Where appropriate, study-specific
values for AUC and DR were pooled using a
random-effects model with weighting by the inverse
of the variance.
Results
NPHS-II and EAS
Association of CRP values with incident CHD
There were 162 incident cases of CHD in NPHS-II and
147 in EAS among the individuals with valid CRP
measurements. Higher CRP concentrations were
associated with a higher risk of CHD events in both
NPHS-II and EAS. In NPHS-II a hazard ratio of 2.22
(95% CI 1.50, 3.30) and EAS a hazard ratio of 1.87
(95% CI 1.21, 2.89) was observed for the comparison
of the top vs bottom tertile of the CRP distribution in
age- and primary-care recruitment centre-adjusted
models. These values were similar in magnitude to
those reported in a previous meta-analysis.6
Effect of CRP on discrimination of CHD
With a CRP cut-point corresponding to a pre-set false-
positive rate of 5% (DR5), the sensitivity for detection
of CHD events was 11.2% in NPHS-II and 10.9% in
EAS, i.e. around 10% of individuals who suffered CHD
events were identified. With a CRP cut-point corre-
sponding to a 10% false-positive rate, the DR (DR10)
was 17.8% in NPHS-II and 19.7% for EAS. Using the
cut-point of 3 mg/l, the positive predictive value was
8.7% in NPHS-II and 20.0% in EAS. The AUC for CRP
in NPHS-II was 0.61 (95% CI 0.57, 0.66), and in EAS
was 0.62 (95% CI 0.57, 0.67). These estimates of the
AUC were modified only minimally when account
was made of the effect of time on the accumulation of
CHD events using Harrell’s C-statistic (Table 1).
Values of the C-statistic for the Framingham-based
model alone and the Framingham plus CRP model
were 0.62 (0.60, 0.65) and 0.66 (0.63, 0.68) in NPHS-
II, and 0.68 (0.64, 0.71) and 0.67 (0.63, 0.71) in EAS,
respectively (Table 1).
Effect of CRP on calibration of risk models based
on Framingham variables
Two risk models were compared in NPHS-II and EAS: a
Cox model derived using Framingham variables, and
the same model with the addition of CRP. Individuals
were first divided into one-fifths of predicted risk and
observed event rates were compared with those
expected. The global fit of the model was improved by
the addition of CRP when assessed by the AIC and the
BIC, which in NPHS and EAS were 2368.6 and 2397.6
for Framingham variables, respectively, and 2355.8 and
2390.5 for Framingham variables plus CRP, respectively
(P< 0.001). However, because statistically significant
improvements in model fit do not necessarily corre-
spond to large absolute differences, we calculated the
ratio of predicted to observed event-rates in each one-
fifth of risk in the two models generated from both
studies (Figure 1). This indicated that the magnitude of
improvement in calibration conferred by adding CRP to
the Framingham model was small and this was
consistent with the Hosmer–Lemeshow P-value which
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Table 1 Relationship between hazard ratio for CHD, AUC and the C-statistic for CRP, established risk predictors, the
Framingham risk score and the Framingham risk score and CRP combined in NPHS II and EAS
NPHS-II EAS
Hazard ratioa
(95%CI)
AUC
(95%CI)
C-indexb
(95%CI)
Hazard ratioa
(95%CI)
AUC
(95%CI)
C indexb
(95%CI)
CRP 2.53 0.61 0.63 1.87 0.62 0.59
(1.44–4.62) (0.57–0.66) (0.60–0.66) (1.21–2.89) (0.57–0.67) (0.54–0.63)
SBP 1.96 0.60 0.59 2.00 0.62 0.58
(1.10–3.50) (0.55–0.64) (0.56–0.62) (1.39–2.89) (0.58–0.66) (0.54–0.62)
TC 1.35 0.59 0.59 1.91 0.62 0.55
(0.75–2.43) (0.55–0.64) (0.56–0.62) (1.32–2.76) (0.58–0.66) (0.51–0.59)
HDL-C 0.74 0.57 0.58 0.56 0.61 0.61
(0.55–0.99) (0.50–0.65) (0.53,0.62) (0.37–0.84) (0.57–0.65) (0.57–0.64)
FRS 1.47 0.62 0.62 4.61 0.65 0.68
(0.68–3.18) (0.57–0.66) (0.60–0.65) (2.98–7.13) (0.61–0.70) (0.64–0.71)
FRSþCRP 2.11 0.64 0.66 3.67 0.65 0.67
(1.04–4.31) (0.60–0.69) (0.63–0.68) (2.16–6.23) (0.61–0.70) (0.63–0.71)
Framingham variables used in NPHS-II were age, smoking, SBP, cholesterol, diabetes.
Framingham variables used in EAS were age, sex, smoking, SBP, cholesterol, HDL, diabetes.
aHazard ratio for top vs bottom tertile adjusted for age, practice, blood pressure, total- and HDL- cholesterol where appropriate.
bPredictive accuracy is calculated as Harrell’s C-index, which extends the AUC to the case of right-censored survival data.
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Figure 1 Predicted and observed risk of CHD based on Cox models derived using traditional risk factors alone and with the
addition of CRP
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indicated that in NPHS-II and EAS studies, models
using Framingham variables alone and Framingham
variables plus CRP were both well calibrated. In NPHS-
II study the Hosmer–Lemeshow P-values were 0.82 for
Framingham without CRP and 0.90 including CRP,
and in the EAS cohort, the P-values were 0.65 for
Framingham without CRP and 0.65 including CRP.
Effect of CRP on prediction using the NRI measure
The reclassification of individuals following the
addition of CRP to a Framingham-based model is
summarized in Table 2 according to the eventual
outcome. In NPHS-II, after generation of four 10-year
CHD risk categories, a total of 716 men (60 cases and
656 controls) were reclassified, of which 368 (51.4%)
moved to higher categories and 348 (48.6%) to lower
categories. Of the 60 cases reclassified, 23 (38%) were
inappropriately reclassified to lower risk categories and
a similar proportion of inappropriate reclassifications
was observed among controls, with 331 (50.5%) out
of 656 controls being reclassified to higher categories.
The NRI was 8.5% (–1.3, 18.3; P¼ 0.09). Very similar
results were observed in the EAS study when using
the same four risk categories (Table 2, panel A).
When two risk-categories were generated using a
treatment threshold for primary prevention of 15%
CHD risk at 10-years, the number of subjects correctly
reclassified by case–control status was substantially
lower. In NPHS-II, in only 10 cases and 18 controls
would the addition of CRP have impacted on the
decision to prescribe statins, with a similarly low
number in the EAS study. Consequently, the NRI
using a treatment threshold of 15% was reduced to
4.9% (0.8–9.0) in NPHS-II and 3.0% (–3.0 to 9.2) in
EAS (Table 2, Panel B).
Distribution of CRP values among cases and controls
In both EAS and NPHS-II, the distribution of CRP
was right-skewed. Log-transformation resulted in
normalization of the distribution in both studies,
with the geometric mean being 2.46 mg/l (approx-
imate SD 2.50 mg/l) in NPHS-II, and 1.93 mg/l
(approximate SD 3.02 mg/l) in EAS. In NPHS-II, the
geometric mean CRP (approximate SD) among the
162 men who later developed CHD was 3.66 (3.66)
mg/l, and 2.40 (2.44) mg/l among the 2317 men who
remained event-free. In EAS, geometric mean CRP
(approximate SD) among the 147 individuals who
later developed CHD was 2.47 (3.01) mg/l, and was
1.85 (3.00) mg/l among the 815 people who remained
event free. Though on average CRP was higher among
individuals who later suffered events, there was
substantial overlap of the log-normal distributions of
CRP values between the two groups (Supplementary
Figure 2), imposing a difficulty in setting a threshold
value for CRP that distinguishes individuals who later
suffer events. Although the risk of CHD events
increased with higher CRP values, 52.4% of CHD
events in NPHS-II and 57.1% events in EAS occurred
among individuals in the middle and lower tertiles of
the CRP distribution (Supplementary Table 1).
When the CRP distribution was divided according to
the cut-points <1, 1–3 and43 mg/l, recommended as
defining individuals at low, intermediate and high
risk, respectively, a similar percentage of events
(41.3% in NPHS-II and 57.1% in EAS) were observed
among individuals at low or intermediate risk
categories.
Systematic review
Reporting of metrics of prediction performance
in published prospective studies
Thirty-one studies of 28 prospective cohorts involv-
ing a total of 84 063 individuals and 11 252 incident
CHD events were identified up to August 2007
(Supplementary Table 4; Supplementary references
W1–W31). Twelve (38.7%) were studies of men alone
(Supplementary references W1, W3, W4, W9–W13,
W17, W18, W21, W25), six (19.4%) were studies of
women alone (Supplementary references W5, W6,
W16, W21, W23, W27) and 13 (41.9%) studies of both
men and women (Supplementary references W2, W7,
W8, W14, W15, W19, W20, W22, W24, W28, W29,
W31).All 31 studies provided a measure of strength of
association. Two studies (6.7%; 20 191 individuals,
531 incident cases) reported the AUC for CRP alone
(Supplementary references W6, W24). A total of 13
studies from the 31 prospective cohorts (42%; 84 292
individuals, 7201 incident cases) reported the effect of
adding CRP to the Framingham model on discrimina-
tion (Supplementary references W6, W8, W13, W15,
W19, W20, W22–W25, W27, W28, W30). One study
(15 048 individuals, 390 incident cases) assessed
reclassification but did not report the NRI measure
(Supplementary references W27). Up to 2003,
only one study had reported on metrics related
directly to predictive performance (Supplementary
reference W6).
Shape of the CHD association and absolute number
of events per CRP quantile in published
prospective studies
Thirty studies (96.8%) reported on the shape of the CRP
distribution, and in all these studies it was reported to
be skewed (Supplementary references W1–W3, W5–
W31). Twenty-one studies (67.7%) reported that
logarithmic transformation normalized the distribu-
tion, (Supplementary references W1–W3, W7–W15,
W17, W20, W22–W24, W28–W31) as observed in
NPHS-II and EAS. Including NPHS-II and EAS, a
total of 12 studies reporting risk according to quartiles
of CRP concentration, and 10 studies reporting risk
according to quintiles, allowed estimation of the shape
of the relationship between log-CRP and log risk of
CHD (Supplementary references W1, W3, W5, W6,
W10, W12–W14, W16–W19, W21, W22, W26). There
were no systematic differences in the characteristics of
studies reporting CRP effects by quartiles or quintiles
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Table 2 NRI in the NPHS-II and EAS studies using Framingham-based models with and without CRP: (A) using four
10-year CHD risk categories and (B) using categories based on a threshold for intervention of a 10-year CHD risk of415%
Panel A
Predicted 10-year CHD risk
Framingham variables plus CRP
No. of individuals Reclassified
Framingham variables <5% 5–10% 10–15% 415% Increased risk Decreased risk
Net correctly
reclassified
NPHS-II study
Individuals without CHD events during follow-up (n¼ 2253)
0–<5% 890 181 0 0 331 325 0.3%
5–10% 242 604 115 4
10–15% 2 63 73 31
515% 0 2 16 30
Individuals with CHD events during follow-up (n¼ 159)
0–<5% 38 10 0 0 37 23 8.8%
5–10% 12 40 17 2
10–15% 0 10 12 8
515% 0 0 1 9
NRI (95% CI) 8.5% (1.3, 18.3)
Edinburgh Artery Study
Individuals without CHD events during follow-up (n¼ 777)
0–<5% 247 23 0 0 83 124 5.3%
5–10% 59 219 32 2
10–15% 0 46 56 26
515% 0 2 17 48
Individuals with CHD events during follow-up (n¼ 142)
0–<5% 18 5 0 0 26 21 3.5%
5–10% 9 29 9 0
10–15% 0 6 27 12
515% 0 1 5 21
NRI (95%CI) 8.8% (1.3 to 18.9)
Panel B
Predicted 10-year CHD risk
Framingham variables plus CRP
No. of individuals Reclassified
Framingham variables 0–15% 515% Increased risk Decreased risk Net correctly reclassified
NPHS-II study
Individuals without CHD events during follow-up (n¼ 2253)
0–15% 2170 35 35 18 0.8%
515% 18 30
Individuals with CHD events during follow-up (n¼ 159)
0–15% 139 10 10 1 5.7%
515% 1 9
NRI (95%CI) 4.9% (0.8, 9.0)
Edinburgh Artery Study
Individuals without CHD events during follow-up (n¼ 777)
0–15% 682 28 28 19 1.2%
515% 19 48
Individuals with CHD events during follow-up (n¼ 142)
0–15% 103 12 12 6 4.2%
515% 6 21
NRI (95%CI) 3.0% (3.0, 9.2)
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(Supplementary Table 2). A linear graded association of
log-CRP values with log risk of events was noted in all
studies (Figure 2). The log-normal distribution of CRP
in populations, coupled with the graded incremental
association of CRP concentration with risk over the
whole range of CRP values, leads to the expectation of
a substantial proportion of all CVD events occurring
among the large number of individuals with near
average levels of CRP. In the eight studies, including
NPHS-II and EAS, that reported the absolute number of
events by tertile; 1772 of 3152 events (56%) occurred
among individuals in the lower and middle tertiles of
the CRP distribution (Supplementary references W2,
W8, W9, W21, W22, W28). In the seven studies,
including NPHS-II and EAS (Supplementary references
W1, W12, W13, W17, W22), that reported absolute
events by quartile, 1105 of 2428 events (46%) occurred
among people in the middle two quartiles. These
proportions were almost identical to those estimated
from the pooled relative risks by quartiles or quintiles
from 18 studies with data available (12 412 individuals,
4651 incident cases) (Figure 2).
Derivation and reporting of measures of predictive
performance of CRP in published prospective studies
Ten studies reported on geometric mean CRP and its
approximate SD separately among incident cases and
those remaining event-free (controls), and seven
studies reported separately on median CRP values
and the inter-quartile range from which the geometric
mean CRP and approximate SD were estimated under
the assumption of a log-normal distribution. For the
remainder of studies where a measure of dispersion
was not reported, a pooled SD was applied. These
were then used to reconstruct the log-normal dis-
tribution of baseline CRP values in the two groups
defined by eventual outcome. In all the 25 studies
with relevant information (40 684 individuals and
9351 cases), there was a substantial overlap of
baseline CRP values among incident cases and
controls (Supplementary Figure 2), similar to that
observed in NPHS-II and EAS.
Estimated disease DRs for a 5% false-positive rate
inferred from these distributions are tabulated
(Table 3) and those for a 10% false-positive rate
shown graphically (Figure 3a), together with esti-
mates of the AUC for CRP from individual studies
(Figure 3b). The estimates were consistent with the
corresponding values from NPHS-II and EAS. Because
it was not possible to estimate the C-statistic from the
summary data, we examined the influence of length
of follow up on the AUC. There was a broad similarity
in the DR10% or AUC estimates in analysis stratified
by mean duration of follow up. The seven studies that
reported on the geometric mean but provided no
measure of dispersion and the single study that
reported the median but provided no inter-quartile
range were similar in other respects to those
that reported these data (Supplementary Table 3).
In the 13 studies that reported on the effect on
the ROC curve or C-statistic of adding CRP to the
Framingham-based models (Supplementary refer-
ences W6, W8, W13, W15, W19, W20, W22–W25,
W27, W28, W30) five reported no change and eight
reported an improvement in the AUC ranging from
0.01 to 0.15 (Figure 4).
(W1;W3;W5;W6;W10;W12-W14;W16-W19;W21;W22;W26)
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Figure 2 Pooled relative risk of CHD: (a) by quartiles and (b) by quintiles of CRP concentration from 12 and 10
prospective studies, respectively. The pooled values were calculated using the inverse variance-weighted method under
random effect models
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Five studies (16.1%; 42 141 individuals, 2430 inci-
dent cases) reported the effect of adding CRP to the
calibration of risk models utilizing traditional risk
factors (Supplementary Table 4; Supplementary refer-
ences W15, W23, W27–W29). The effect of adding
CRP to a base model was assessed in a variety of ways
across studies, precluding pooled analyses. However,
regardless of the metric used or reported statistical
significance, absolute improvements if present were
small.
Two reports from the Women’s Health Study
(Supplementary reference W27, 38), examined the
effect of adding CRP to models based on established
risk factors using reclassification tables. Both studies
Table 3 Prospective studies from which measures of discrimination were inferred
Study
(year pub) Data set
Men
(%)
Mean
follow-
up (yrs)
Primary
endpoint
Geometric mean
CRP casesa
(mg/l) (SD)
Number
cases
Geometric mean
CRP controlsa
(mg/l) (SD)
Number
controls
Mean DR5
95%CIb
(computed)
Kuller (1996) MRFIT 100 17 CHD 3.4b 148 2.9b 296 6.3 (2.4–10.3)
Ridker (1997) PHS 100 14 CVD 1.37b 543 1.10b 543 6.9 (4.8–9.1)
Ridker (1998) WHS 0 3 CVD 6.45a 122 3.75a 244 10.8 (5.3–16.3)
Jager (1999) Hoorn 48 5 CVD
mortality
3.33a (4.1) 58 1.68a (1.9) 573 15.5 (6.2–24.9)
Packard (2000) WOSCOPS 100 6 CHD 2.36 (2.81) 580 1.88 (2.92) 1160 6.8 (4.8–8.9)
Roivainen
(2000)
HHS 100 8.5 CHD 4.44b 241 2.01b 241 14.6 (10.2–19.1)
Pradhan (2002) WHI-OS 0 2.9 CHD 3.3a (4.2) 304 2.5a (2.7) 304 7.9 (4.9–11.0)
Sakkinen (2002) Honolulu 100 20 CHD 0.81 (0.7) 369 0.60 (0.5) 1348 9.8 (6.8–12.9)
Folsom (2002) ARIC
(87-93)
66 6 CHD 3.5b 242 2.3b 590 9.2 (5.5–12.8)
Folsom (2002) ARIC
(90-95)
66 5 CHD 2.3b 373 1.3b 590 11.2 (8.0–14.3)
Luc (2003) PRIME 100 5 CHD 2.0a (2.1) 317 1.33a (1.5) 609 10.2 (6.8–13.5)
Van der Meer
(2003)
Rotterdam 45.5 5 CHD 2.18a (3.0) 157 1.68a (1.6) 500 8.2 (3.9–12.5)
Lowe (2004) Caerphilly 100 8.75 CHD 2.26 (3.5) 189 1.66 (1.8) 1334 9 (4.9–13.0)
Lowe (2004) Speedwell 100 6.25 CHD 2.36 (2.9) 162 1.5 (1.9) 1528 10.7 (5.9–15.4)
Danesh (2004) Reykjavik 70.3 20.6 CHD 1.75 (5.3) 2459 1.28 (5.2) 3969 5.8 (4.9–6.8)
Pai (2004) NHS 0 8 CHD 3.1a (4.6) 239 2.2a (3.0) 469 8.6 (5.0–12.1)
Pai (2004) HPFS 100 6 CHD 1.68a (1.8) 265 1.08a (1.4) 529 10.7 (6.9–14.4)
Cushman (2005) CHS 42 10 CHD 1.98b 547 1.64b 3424 6.6 (4.5–8.7)
St. Pierre (2005) QCS 100 13 CHD 2.2 (3.2) 210 1.8 (3.1) 1772 6.3 (3.0–9.6)
Boekholdt (2005) EPIC-N 63 6 CHD 2.1a (2.5) 770 1.4a (1.8) 1515 9.9 (7.8–12.1)
Koenig (2006) MONICA 55 11 CHD 2.6 (2.4) 382 1.4 (2.65) 1980 9.8 (6.8–12.7)
Sattar (2007) PROSPER 48 3.2 CVD 3.64 (3.08) 865 3.01 (3.05) 4815 7.3 (5.6–9.0)
Erbel (2007) Heinz
Nixdorf
100 4 CAD 1.7a 218 1.3a 1918 7.4 (3.9–10.9)
Erbel (2007) Heinz
Nixdorf
0 4 CAD 2.5a 62 1.4a 2148 11.3 (3.4–19.2)
Woodward
(2007)
Fletcher
Challenge
study
72 5.5 CHD 3.81 (9.9) 220 2.01 (2.98) 411 9.4 (5.5–13.3)
aMedian CRP values and approximate SD calculated from interquartile range. bSD not available.
MRFIT, Multiple Risk Factor Intervention Trial; PHS, Physicians Health Study; WHS, Womens Health Study; WOSCOPS, West of
Scotland Coronary Prevention Study; HHS, Helsinki Heart Study; WHI-OS, Womens Health Initiative Observational Study; PRIME,
Prospective Epidemiological Study of Myocardial Infarction; NHS, Nurses Health Study; HPFS, Health Professionals Follow-up
Study; CHS, Cardiovascular Health Study; QCS, Quebec Cardiovascular Study; EPIC-N, European Prospective Investigation
of Cancer at Norfolk; MONICA, MONitoring in CArdiovascular diseases; PROSPER, Prospective Study of Pravastatin in the Elderly
at Risk.
(Supplementary references W1-W3;W5-W14;W16-W22;W26-W31)
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focused on event rates among individuals who shifted
risk category on the addition of CRP, concluding that
the actual risk of these individuals was more
accurately assigned by the addition of CRP to the
risk model. A comparison of observed risk in each
category of predicted risk in NPHS-II and EAS
(Table 4) that included all individuals in each
category of predicted risk (i.e. those that shifted as
well as those that did not) and a similar re-analysis of
information from references W27 and 38 (data not
shown) indicated that models that included or
omitted CRP performed similarly. Moreover, the
number of individuals that were reclassified between
two risk categories based on a threshold 10-year CVD
risk of 20% in WHS was 40 (0.15%) individuals who
shifted above the threshold and 30 subjects (0.11%)
who moved below the threshold. In the remaining 26
857, reclassification would not have affected decisions
on the prescription of statins for primary prevention if
these were based on a 20% CVD risk threshold. It was
not possible to assess the number of individuals for
whom reclassification was appropriate using the NRI
measure, as the data were not presented separately by
case–control status.
Discussion
In a new analysis of two prospective cohorts and a
critical appraisal of published studies of CRP, we
found consistent reporting of measures of association
relevant to aetiological analysis, but variable reporting
of measures more directly relevant to the predictive
utility of a marker. Collation of the available evidence,
drawing together information on the different mea-
sures of prediction (both reported and imputed)
indicated that while consistently associated with
CHD risk, CRP measurement provides variable, gen-
erally modest, though sometimes statistically signifi-
cant improvement in risk prediction. This analysis
helps rationalize the available evidence to help
Figure 3 Study-specific estimates of: (a) sensitivity (for a 10% false-positive rate; DR10) and (b) AUC for CRP obtained
directly in NPHS-II, EAS and inferred from data extracted from 25 published reports. A sensitivity analysis by duration of
follow up is also shown. The pooled values were calculated using the inverse variance-weighted method under random
effect models
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clinicians, health providers and patients decide about
whether or not measurement of CRP should be
incorporated in the evaluation of CHD or CVD risk.
The findings are also relevant to the conduct and
reporting of studies of other emerging biomarkers
being evaluated for CHD prediction and inform the
debate on the optimal strategy for primary prevention
of CHD.
Predictive performance of CRP
Discrimination
One recommendation of the 2006 NHLBI workshop
on CRP was research to assess ‘whether replacing a
traditional risk factor(s) with CRP (or other newly
discovered risk predictors) could improve CVD risk
prediction’, (http://www.nhlbi.nih.gov/meetings/work
shops/crp/report.htm). In the NPHS-II and EAS
studies, measurement of CRP in individuals healthy
at baseline provided limited discrimination for CHD
events. CRP cut-points set to reduce misclassification
(false-positive) rates to 5% or 10%, only detected
between 10% and 20% of the people who eventually
had events. The previously recommended CRP cut-
point of 3 mg/l provided similarly modest discrimina-
tion. Discrimination over a range of cut-point values
is summarized quantitatively as the AUC, which was
0.61 (0.57, 0.66) in NPHS-II, and 0.62 (0.57, 0.67) in
EAS where 0.5 represents no discrimination and 1
represents perfect discrimination. Harrell’s C-statistic
was also not substantially different from the AUC in
NPHS-II and EAS. The findings in NPHS-II and EAS
were concordant with data obtained from prior
reports identified by systematic review. Because of
the variable reporting of the metrics relevant for
assessing discrimination, these were derived, where
Figure 4 Observed AUC or C-statistic for Framingham-based models with and without the addition of CRP in NPHS-II,
EAS and six published studies reporting these data with measures of dispersion. AUC or C-statistic for a further seven
studies that did not report measures of dispersion were: Ridker 2002, 0.81 for Framingham alone and 0.81 for Framingham
plus CRP; Koenig 2006, 0.735 for Framingham alone and 0.75 for Framingham plus CRP; St Pierre 2005, 0.74 for
Framingham alone and 0.74 for Framingham plus CRP; Folsom 2006, 0.705 for Framingham alone and 0.706 for
Framingham plus CRP; Cook 2006, 0.767 for Framingham alone and 0.77 for Framingham plus CRP; Sattar 2007, 0.813 for
Framingham alone and 0.815 for Framingham plus CRP; Cao 2007, 0.63 for Framingham alone and 0.637 for Framingham
plus CRP (Supplementary references W6, W8, W13, W15, W27, W28, W30)
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possible, using study-specific summary CRP values
from cases and controls. The derived values for
disease DRs and the AUCs for CRP (Table 3 and
Figure 3) were concordant with those obtained by
direct calculation in NPHS-II and EAS, providing
evidence for consistency across studies.
Another proposed application is to add CRP to
established predictors included in the Framingham
model. In NPHS, EAS and in the 13 prospective
studies that evaluated the effect of adding CRP to the
Framingham risk equation (Figure 4), CRP provided
either very small or no improvement in the AUC or
C-statistic.
Calibration
Calibration refers to the ability of a risk model to
predict the observed risk in a group of individuals.
Risk models are used clinically to target treatments
for primary prevention to those at highest risk in
order to enhance cost effectiveness and reduce
unnecessary exposure to drugs. However, the addition
of CRP to models based on established markers
included in the Framingham equation did not
substantially enhance the calibration in NPHS and
EAS (Figure 1). Of the five published studies that
evaluated the effect of adding CRP to the calibration
of risk models, assessment was made in different
ways but none appeared to identify a quantitatively
large improvement in model fit, though statistically
significant differences were sometimes judged as
being clinically important.
Reclassification
Because of concerns that neither discrimination nor
calibration provides a fair test of a new marker, we
also studied the effect of adding CRP to established
risk assessment methods using the NRI measure.
Although this analysis breaks a continuous risk score
into categories, it can be informative in assessing how
the addition of a marker to a base model reassigns
risk in those who do or do not suffer clinical events.
When CRP was added to a Framingham-based model
using four categories of 10-year CHD risk in NPHS-II
and EAS, the proportion of subjects correctly reclassi-
fied (risk upgraded in eventual cases and risk down-
graded in people remaining healthy) was almost
matched by the proportion incorrectly reclassified, so
that the NRI was only 8.5% (–1.3, 18.3) in NPHS-II
and 8.8% (–1.3, 18.9) in EAS. When two risk
categories were considered based on an individual
traversing the 15% 10-year risk cut-point for initiating
statin therapy for primary prevention, the NRI was
reduced still further to 4.9% (0.8, 9.0) in NPHS-II and
3.0% (–3.0, 9.2) in EAS. Thus, in absolute terms,
measurement of CRP in all 2479 men in NPHS-II
would have led to a change in the decision to
recommend statin therapy in only 11 individuals;
statins would have been given to an additional 10
individuals, and withheld from one, and the cost
effectiveness of such an approach has yet to be
adequately assessed. Very similar results were
observed in EAS (Table 2). Only one study previously
reported the ability of CRP to reclassify subjects into
risk categories. Only 70 of the 26 927 participants
(0.26%) crossed the 10-year 20% CHD risk threshold
following addition of CRP, but it was not possible
from the data provided to derive the NRI in the
absence of information on the eventual outcome
among reclassified individuals. In NPHS-II and EAS,
in direct comparisons of models that included or
excluded CRP using reclassification tables that com-
pare observed (actual) risk with predicted risk, there
was very little overall difference in alignment between
the two models (Table 4). Thus, overall, the available
evidence from NPHS and EAS as well as published
prospective studies indicated that the incremental
predictive performance of CRP in CHD is limited
when added to conventional risk factors, regardless of
the metric utilized.
Factors that constrain the predictive
performance of CRP in CHD
Why should CRP, a sensitive marker of the inflam-
matory processes linked to atherosclerosis32 and
consistently associated with CHD risk, predict cases
of CHD only modestly well? One important reason
could lie in the fundamental relationships that
determine the predictive performance of a marker.
First, the distribution of CRP values in all populations
studied was log-normal. Second, using pooled data
from 18 studies, we identified a graded continuous
relationship of CRP with risk of CHD, over the full
range of CRP values observed in general populations,
without a threshold. Thus, a substantial proportion of
Table 4 Observed event rate (risk) of CHD for different
categories of predicted risk assessed using models
incorporating or omitting CRP
Category of predicted riska
0 to
<5%
5 to
<10%
10 to
<15% 415%
Proportion
Reclassified
(%)
NPHS-II
Without CRP 1119 1036 199 58
4.3% 6.9% 15.1% 17.2%
With CRP 1184 910 234 84 716/2412
4.2% 6.6% 12.8% 22.6% (29.7%)
EAS
Without CRP 243 359 173 94
4.3% 7.8% 21.9% 22.8%
With CRP 333 331 146 109 254/919
4.3% 8.4% 20.5% 26.1% (27.6%)
aRisk is 10-year risk in NPHS-II and EAS. Values in cells are
total number of individuals in each predicted risk category, and
10 year event rate (%).
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all CHD events would be expected among the many
individuals with near average levels of CRP, who are
at intermediate risk of disease. This was observed in
NPHS-II and EAS, as well as in 25 other studies that
provided the relevant information. This likely con-
tributes to the substantial overlap of CRP values
among incident cases and controls (Supplementary
Figure 2) that in turn, explains the small to moderate
size of the association of CRP with CHD (an odds
ratio of around two for a two SD difference in CRP).
It also accounts for the difficulty in establishing a cut-
point for CRP that adequately distinguishes those
who suffered events, summarized quantitatively by
the AUC.
Additional reasons are likely to contribute to the
limited incremental utility for discrimination when
CRP is added to standard risk assessment. First, it has
been shown that combining markers that exhibit
modest discrimination individually adds less than
might be expected to the discrimination of a multi
marker model.26 Second, it is recognized that CRP is
not only associated with blood pressure, LDL- and
HDL-cholesterol, age and gender, but also with
diabetes, smoking, left ventricular hypertrophy and
atrial fibrillation, all of which already contribute to
the Framingham risk model.33–35 In some studies, the
proportion of high CRP levels attributed to traditional
risk factors was as high as a 78% in men and 67% in
women.36 This was borne out empirically in the 15
prospective studies that reported the AUC or the C-
statistic for Framingham model with and without
CRP (Figure 4). It is likely that similar constraints
limit the degree to which addition of CRP recalibrates
risk models or improves classification.
Limitations and strengths
Some of the limitations of our study are worthy of
consideration. First, not all studies reported the full
range of metrics relevant for prediction. This was, in
large part, the motivation for our critical appraisal.
Nevertheless, we found no systematic differences in
the characteristics of the studies reporting different
metrics. Moreover, the fundamental relationships that
constrain marker performance, namely the log-normal
distributions of CRP values overall and the moderate,
graded log-linear association with risk were more
widely reported and were consistent across all studies.
Where we derived metrics relevant to prediction from
the published studies, we used aggregate rather than
participant-level data with the assumption that the
CRP distribution is log normal among both incident
cases and controls. However, all the derived metrics
and estimated relationships in published data were
directly verifiable in EAS and NPHS-II, and all were
closely concordant. Participant-level information
would allow more detailed analyses, and this may
become possible through resources being built by the
Emerging Risk Factors Collaboration. We did not
formally assess the possibility of publication bias in
this analysis, although this was addressed by a
previous meta-analysis.6 However, unpublished stu-
dies, should they exist, are more likely to attenuate,
rather than inflate the estimates of predictive utility.
Lastly, although CRP may have limited utility in the
screening or prediction of CHD, there is also immense
interest in the possibility that it may be causally
involved in the development and progression of
atheroma or its complications after an acute event37
and our analysis was not designed to address this.
Nor did our analysis address the utility of CRP for risk
stratification around the time of an acute coronary
syndrome, nor its potential pathological role in
ischaemic tissue damage.
Implications for evaluation of other
novel markers
Twenty-five years ago more than 240 ‘risk factors’ for
CHD had already been identified, and many new
markers have since been added. The pace of discovery
of new markers is expected to accelerate with the new
-OMICs technologies, and it is likely that one or more
of these newly identified markers will be advocated
for risk prediction in the same way as CRP. However,
it is imperative that the utility of any marker is
assessed using the appropriate metrics and not simply
based on tests of ‘independent’ association that
provide insufficient evidence on predictive utility.
Better appreciation of the fundamental epidemiologi-
cal relationships that constrain the performance of all
novel markers will also be required; namely, the
distribution in a population and the shape and
strength of the association with CHD.
Conclusions
In summary, new studies and a systematic review of
published data indicate that while CRP is consistently
associated with CHD and CVD risk, measurement of
CRP provides much more limited information for risk
prediction than tests of association alone might
indicate. Previous guidance on the clinical use of
CRP measurement may require updating in the light
of these findings. Analyses of the type reported in this
paper for CRP, could be also conducted for other
novel biomarkers, to test whether or not any of these
are likely to help better predict the occurrence of
coronary events. All such analyses would benefit from
the development of reporting standards to facilitate
critical evaluation of the performance of biomarkers
advocated for risk prediction.
Supplementary data
Supplementary data are available at IJE online.
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The only relevant test of the validity of a hypothesis is
comparison of prediction with experience
Milton Friedman
Introduction
The last three decades have seen major advances in
our understanding of the pathogenesis of coronary
heart disease (CHD), with substantial improvements
in our management of patients at risk of disease
and of those who have suffered a coronary event.
The multifactorial nature of coronary disease and
its evolution as a life course disease1 due to the
combined influences of genetic and lifestyle-related
factors are firmly accepted concepts. We no longer
argue about the role of cholesterol and its compo-
nents as critical mediators of the disease, nor dispute
whether the occlusive thrombus in the coronary
tree in a patient with a myocardial infarction
antedates or follows the clinical event. However,
the debates in cardiology continue to rage with a
shifting of the themes. One such contemporary con-
troversy centres on if, when, and how novel
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